BACKGROUND: Flavopiridol, a Cdk inhibitor, potentiates irinotecan-induced apoptosis. In a phase I trial of sequential irinotecan and flavopiridol, 2 patients with advanced hepatocellular carcinoma (HCC) had stable disease (SD) for ≥14 months. We thus studied the sequential combination of irinotecan and flavopiridol in patients with HCC. METHODS: Patients with advanced HCC naïve to systemic therapy, Child-Pugh ≤B8, and Karnofsky performance score (KPS) ≥70% received 100 mg/m(2) irinotecan followed 7 hours later by flavopiridol 60 mg/m(2) weekly for 4 of 6 weeks. The primary end point was an improvement in progression-free survival at 4 months (PFS-4) from 33% to 54%, using a Simon's two-stage design. Tumors were stained for p53. RESULTS: Only 16 patients in the first stage were enrolled: median age, 64 years; median KPS, 80%; Child-Pugh A, 87.5%; and stage III/IV, 25%/75%. The primary end point was not met; PFS-4 was 20%, leading to early termination of the study. Ten patients were evaluable for response: 1 had SD >1 year and 9 had disease progression. Grade 3 fatigue, dehydration, diarrhea, neutropenia with or without fever, lymphopenia, anemia, hyperbilirubinemia, and transaminitis occurred in ≥10% of the patients. Of the 9 patients who progressed, 5 had mutant p53 and 4 had wild-type p53. The patient with stable disease had wild-type p53. CONCLUSION: Sequential irinotecan and flavopiridol are ineffective and poorly tolerated in patients with advanced HCC. Despite our limited assessments, it is possible that the presence of wild-type p53 is necessary but not sufficient to predict response in HCC.
BACKGROUND:Flavopiridol, a Cdk inhibitor, potentiates irinotecan-induced apoptosis. In a phase I trial of sequential irinotecan and flavopiridol, 2 patients with advanced hepatocellular carcinoma (HCC) had stable disease (SD) for ≥14 months. We thus studied the sequential combination of irinotecan and flavopiridol in patients with HCC. METHODS:Patients with advanced HCC naïve to systemic therapy, Child-Pugh ≤B8, and Karnofsky performance score (KPS) ≥70% received 100 mg/m(2) irinotecan followed 7 hours later by flavopiridol 60 mg/m(2) weekly for 4 of 6 weeks. The primary end point was an improvement in progression-free survival at 4 months (PFS-4) from 33% to 54%, using a Simon's two-stage design. Tumors were stained for p53. RESULTS: Only 16 patients in the first stage were enrolled: median age, 64 years; median KPS, 80%; Child-Pugh A, 87.5%; and stage III/IV, 25%/75%. The primary end point was not met; PFS-4 was 20%, leading to early termination of the study. Ten patients were evaluable for response: 1 had SD >1 year and 9 had disease progression. Grade 3 fatigue, dehydration, diarrhea, neutropenia with or without fever, lymphopenia, anemia, hyperbilirubinemia, and transaminitis occurred in ≥10% of the patients. Of the 9 patients who progressed, 5 had mutant p53 and 4 had wild-type p53. The patient with stable disease had wild-type p53. CONCLUSION: Sequential irinotecan and flavopiridol are ineffective and poorly tolerated in patients with advanced HCC. Despite our limited assessments, it is possible that the presence of wild-type p53 is necessary but not sufficient to predict response in HCC.
Authors: Y N Chen; S K Sharma; T M Ramsey; L Jiang; M S Martin; K Baker; P D Adams; K W Bair; W G Kaelin Journal: Proc Natl Acad Sci U S A Date: 1999-04-13 Impact factor: 11.205
Authors: R Soong; P D Robbins; B R Dix; F Grieu; B Lim; S Knowles; K E Williams; G R Turbett; A K House; B J Iacopetta Journal: Hum Pathol Date: 1996-10 Impact factor: 3.466
Authors: E M O'Reilly; K E Stuart; P M Sanz-Altamira; G K Schwartz; C M Steger; L Raeburn; N E Kemeny; D P Kelsen; L B Saltz Journal: Cancer Date: 2001-01-01 Impact factor: 6.860
Authors: G Kaur; M Stetler-Stevenson; S Sebers; P Worland; H Sedlacek; C Myers; J Czech; R Naik; E Sausville Journal: J Natl Cancer Inst Date: 1992-11-18 Impact factor: 13.506
Authors: D M Tolbert; A E Noffsinger; M A Miller; G W DeVoe; G N Stemmermann; J S Macdonald; C M Fenoglio-Preiser Journal: Mod Pathol Date: 1999-01 Impact factor: 7.842
Authors: Olivia Perwitasari; Xiuzhen Yan; Jason O'Donnell; Scott Johnson; Ralph A Tripp Journal: Assay Drug Dev Technol Date: 2015-07-20 Impact factor: 1.738